AJMC Contributor

A group of researchers has compiled the latest advancements in preventing and treating graft-vs-host disease (GVHD).

Increased interest in screening for the genetic risk of type 1 diabetes (T1D) has been driven by factors including the introduction of immune interventions.

The group showed that their 14-day model using an easily measurable calculation was able to predict long-term mortality as well as the traditional model using responses from 2 weeks later.

Among food-insecure patients on antihypertensive medication, receiving assistance through the Supplemental Nutrition Assistance Program (SNAP) was associated with improvements in medication adherence.

The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an increased of or protective effect against MG.

Researchers of the review are underscoring the potential for economic policies to improve the management of hypertension for the millions of people throughout the United States with the condition who are at risk for cardiovascular disease.

Based on data from the study, a phase 3 confirmatory trial is underway for the humanized monoclonal antibody.

Outside of genetics, which has a well-documented link to the risk of type 1 diabetes (T1D), investigators detail available research spanning a variety of factors, including viral infections, pesticide exposure, and the gut microbiome.

Using home insulin pumps when hospitalized was relatively safe compared with hospital-managed pumps and insulin injections among more than 2700 children admitted to a single hospital center.